Millie
your market intelligence analyst
Search Results
91 results
Your search is now limited to «Non-Hodgkin Lymphoma» expert search.
Pharmafile 08/05/2020 07:11
NICE has announced its rejection of Ledaga (chlormethine gel), a topical therapy for the treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL), a type of non-Hodgkin’s lymphoma. The institute said it made the decision because it could not determine the efficacy of the therapy versus standard care.
More from Pharmafile:
GlobeNewswire 08/04/2020 01:15
Novartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma Swiss Stock Exchange:NOVN.
More from GlobeNewswire:
Business Wire 07/31/2020 19:51
PLANEGG, Germany & MUNICH & WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--FDA Approves Monjuvi® (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory DLBCL.
More from Business Wire:
Healio News 07/24/2020 16:44
Our armored CAR T cells achieved a significant anti-bulky lymphoma response while causing limited and tolerated cytokine release syndrome and central nervous system toxicity.
More from Healio News:
ClinicalTrials.gov 07/21/2020 08:23
Condition : Peripheral T-cell Lymphoma Interventions : Drug: Azacitidine; Drug: Chidamide Sponsor : Ruijin Hospital Recruiting.
More from ClinicalTrials.gov:
In the expansion phase, patients with lymphoma were enrolled in five disease cohorts at the MTD.
More from Clinical Cancer Research - Recent Issues (abstracts):
Hoffmann-La Roche (EU) 07/14/2020 01:03
This designation was granted based on encouraging efficacy results observed in the phase I/Ib GO29781 study [NCT02500407] investigating mosunetuzumab in R/R non-Hodgkin lymphoma (NHL.
More from Hoffmann-La Roche (EU):
PubMed News (NIH) 07/06/2020
Contributor : Naohiro Sekiguchi Series Type : Expression profiling by array Organism : Homo sapiens. Bone lesion in waldenstom macroglobulinemia (WM) is less common. In the present study, we compaired gene expresion signature of bone lesion in WM compaired to multiple myeloma (MM). In WM, APRIL and HBGB1 were up-regulated compaired to MM.
More from PubMed News (NIH):
Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date.
More from International Journal of COPD:
Top Class Actions 07/03/2020 09:00
Consumers and scientists have speculated for many years about possible links between non-Hodgkin lymphoma and the use of herbicides that contain glyphosate, the main active ingredient in the best-selling weed killer Roundup.
More from Top Class Actions:
Extranodal natural killer/T-cell lymphoma (ENKTCL) is an aggressive hematological malignancy and accounts for 5.2% and 3% of all non-Hodgkin lymphoma in the Far East and Central/South America, respectively.(1,2) Chinese statistics disclosed that ENKTCL constituted 6.4% of non-Hodgkin lymphoma, and more than 20% of mature T- and NK-cell lymphoma.(3) ENKTCL shows a predilection for population with EBV infection and shares strong associations with Asian genetic background.(1,4,5) However, both the pathogenesis of ENKTCL and the significant role of EBV during the lymphomagenesis remain largely unknown.
More from Cancer Treatment Reviews (Abstract):
PR Newswire 06/23/2020 07:30
The iNNOVATE study continues to deliver strong clinical evidence supporting the long-term use of ibrutinib plus rituximab across first and second lines of therapy for patients with Waldenström's macroglobulinemia.
More from PR Newswire:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications